Monday, December 1, 2014
A New Combined Approach to Cancer Immunotherapy is Needed
A New Combined Approach to Cancer Immunotherapy is Needed Today – 17:42 GMT NEW YORK, NY/ ACCESSWIRE/ December 1, 2014/ With the recent insolvency of Dendreon Company (NASDAQ: DNDN) due to unsatisfactory sales of its crown jewel Provenge prostate cancer injection, the future of cancer cells immunotherapy simply got a [...] Read More
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment